JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Formulation and Cytotoxicity of Ribosome-Inactivating Protein Mirabilis Jalapa L. Nanoparticles Using Alginate-Low Viscosity Chitosan Conjugated with Anti-Epcam Antibodies in the T47D Breast Cancer Cell Line
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Formulation and Cytotoxicity of Ribosome-Inactivating Protein Mirabilis Jalapa L. Nanoparticles Using Alginate-Low Viscosity Chitosan Conjugated with Anti-Epcam Antibodies in the T47D Breast Cancer Cell Line
Wicaksono, Psycha Anindya; Sismindari, Sismindari; Martien, Ronny; Ismail, Hilda;
  PDF(new window)
 Abstract
Ribosome-inactivating protein (RIP) from Mirabilis jalapa L. leaves has cytotoxic effects on breast cancer cell lines but is less toxic towards normal cells. However, it can easily be degraded after administration so it needs to be formulated into nanoparticles to increase its resistance to enzymatic degradation. The objectives of this study were to develop a protein extract of M. jalapa L. leaves (RIP-MJ) incorporated into nanoparticles conjugated with Anti-EpCAM antibodies, and to determine its cytotoxicity and selectivity in the T47D breast cancer cell line. RIP-MJ was extracted from red-flowered M. jalapa L. leaves. Nanoparticles were formulated based on polyelectrolyte complexation using low viscosity chitosan and alginate, then chemically conjugated with anti-EpCAM antibody using EDAC based on carbodiimide reaction. RIP-MJ nanoparticles were characterised for the particle size, polydispersity index, zeta potential, particle morphology, and entrapment efficiency. The cytotoxicity of RIP-MJ nanoparticles against T47D and Vero cells was then determined with MTT assay. The optimal formula of RIP-MJ nanoparticles was obtained at the concentration of RIP-MJ, low viscosity chitosan and alginate respectively 0.05%, 1%, and 0.4% (m/v). RIP-MJ nanoparticles are hexagonal with high entrapment efficiency of 98.6%, average size of 130.7 nm, polydispersity index of 0.380 and zeta potential +26.33 mV. The values of both anti-EpCAM-conjugated and non-conjugated RIP-MJ nanoparticles for T47D cells (13.3 and ) were lower than for Vero cells (27.8 and ). The values of conjugated and non-conjugated RIP-MJ for both cells were much lower than values of non-formulated RIP-MJ (>).
 Keywords
Ribosome-inactivating protein;Mirabilis jalapa L. nanoparticle;chitosan;alginate;anti-EpCAM;
 Language
English
 Cited by
1.
Folate-Targeted Nanostructured Lipid Carriers (NLCs) Enhance (Letrozol) Efficacy in MCF-7 Breast Cancer Cells,;;;;;

Asian Pacific Journal of Cancer Prevention, 2016. vol.17. 12, pp.5185-5188 crossref(new window)
1.
A new age for biomedical applications of Ribosome Inactivating Proteins (RIPs): from bioconjugate to nanoconstructs, Journal of Biomedical Science, 2016, 23, 1  crossref(new windwow)
 References
1.
Amidi M, Mastrobattista E, Jiskoot W, et al (2010). Chitosan-Based delivery systems for protein therapeutics and antigens. Advanced Drug Delivery Rev, 62, 59-82. crossref(new window)

2.
Anonim (2008). Carbodiimides (EDAC) Heterobifunctionnal cross-linkers, http://www.interchim.fr/ft/5/52005A.pdf, Accessed on 21 November 2013.

3.
Baeuerle P, Gires O (1993). EpCAM (CD326) finding it is role in cancer. Br J Cancer, 96, 417- 23.

4.
Barbieri L, Batelli MG, Stirpe F (1993). Ribosome-inactivating proteins from plants. Biochim Biophys Acta, 1154, 237-82. crossref(new window)

5.
Bradford MM (1976). Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 72, 248-54. crossref(new window)

6.
De Campos AM, Diebold Y, Carvalho ELS, et al (2004). Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity. Pharm Res, 21, 803-10. crossref(new window)

7.
Frokjaer S, Otzen DE (2005). Protein drug stability: a formulation challenge, Nat Rev Drug Discov, 4, 298-306. crossref(new window)

8.
Gan Q, Wang T (2007). Chitosan nanoparticle as protein delivery carrier-systematic examination of fabrication conditions for efficient loading and release. Colloids Surf B: Biointerfaces, 59, 24-34.

9.
Gombotz WR, Wee SF (1998). Protein Release from alginate matrices. Adv Drug Deliver Rev, 31, 267-85. crossref(new window)

10.
Grenha A, Seijo B, Remunan-Lopez C, et al (2005). Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Sci, 25, 427-37. crossref(new window)

11.
Gupta RB (2006). Fundamentals of drug nanoparticles in nanoparticle technology for drug delivery, Eds Gupta RB and Kompella UB. Taylor & Francis Group, New York pp 1-9.

12.
Hamman JH (2010). Chitosan based polyelectrolyte complexes as potential carrier materials in drug delivery systems. Marine Drugs, 8, 1305-22. crossref(new window)

13.
Hartig SM, Greene RR, Dikov MM, et al (2007). Multifunctional nanoparticulate polyelectrolyte complexes. Pharm Res, 24, 2353-69. crossref(new window)

14.
Hashimoto M, Yang Z, Koya Y, et al (2005). Chitosan in nonviral gene therapy, gene design and delivery, Eds Taira K, Kataoka K, and Niidome T. Springer-Verlag, Tokyo, 63-74.

15.
Hu C, Chiang C, Yeh (2012). Influence of charge on FITCBSA-loaded chondroitin sulfate-chitosan nanoparticles upon cell uptake in human Caco-2 cell monolayers. Int J Nanomedicine, 7, 4861-72.

16.
Hussaana A, Chodidjah, Sismindari, et al (2010). Mekanisme in vitro induksi apoptosis dari RIP (Ribosome-Inactivating Protein) daun bunga pukul empat (Mirabilis jalapa L). Jurnal Sains Medika, 2, 23-31.

17.
Ikawati Z, Sudjadi, Sismindari (2006). Cytotoxicity against tumor cell lines of a Ribosome-lInactivating Protein (RIP)-like protein isolated from Leaves of Mirabilis jalapa L. Malay J Pharm Sci, 4, 31-41.

18.
Indrayudha P, Wijayanti N, Sismindari (2011). Antiangiogenesis activity of protein fraction containing MJ-C acidic ribosomeinactivating protein of Mirabilis jalapa L. Jurnal Bahan Alam Indonesia, 7, 277-81.

19.
Kimman M, Norman R, Jan S, et al (2012). The burden of cancer in member countries of the association of Southeast Asian nations (ASEAN). Asian Pac J Cancer Prev, 13, 411-20. crossref(new window)

20.
Kocbek P, Obermajer N, Cegnar M, et al (2007). Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Controlled Release, 120, 18-26. crossref(new window)

21.
Ling J, Liu W, Wang TP (2009). Cleavage of supercoiled doublestranded DNA by several ribosome-inactivating proteins in vitro. FEBS Lett, 345, 143-6.

22.
Lu F, Wu SH, Hung Y, et al (2009). Size effect on cell uptake in well-suspended. Uniform Mesoporous Silica Nanoparticles. Small, 5, 1408-13. crossref(new window)

23.
Mohanraj VJ, Chen Y (2006). Nanoparticles-a review. Tropical J Pharmaceutical Res, 5, 561-73.

24.
Mosmann T (1983). Rapid colorimetric sssay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods, 65, 55-63. crossref(new window)

25.
Nidhin M, Indumathy R, Sreeram KJ, et al (2008). Synthesis of iron oxide nanoparticles of narrow size distribution on polysaccharide templates. Bull Mater Sci, 31, 93-6. crossref(new window)

26.
Osta WA, Chen Y, Mikhitarian K, et al (2004). EpCAM is overexpressed in breast cancer and it is a potential target for breast cancer gene therapy. Cancer Res, 64, 5818-24. crossref(new window)

27.
Panyam J, Labhasetwar V (2003). Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Advanced Drug Delivery Rev, 55, 329-47. crossref(new window)

28.
Peer D, Karp JM, Hong S, et al (2007). Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnol, 2, 751-60. crossref(new window)

29.
Sarmento B, Ribeiro, Veiga F, et al (2007). Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm Res, 24, 2198-206. crossref(new window)

30.
Saether HV, Holme HK, Maurstad G, et al (2008). Polyelectrolyte complex formation using alginate and chitosan. Carbohydr Polym, 74, 813-21. crossref(new window)

31.
Sismindari, Husaana A, Mubarika S (1998). In vitro cleavage of supercoiled DNA by Annona squamosa extract. MFI, 9, 146-52.

32.
Sismindari, Hartati MS, Adhyatmika, et al (2010). Cytotoxic selectivity of MJC0.3 and MJC0.5, acidic ribosomeinactivating proteins isolated from Mirabilis jalapa L. leaves against various cancer cell lines. J Med Sci, 42, 39-43.

33.
Sterzynska K, Kempisty B, Zawierucha P, et al (2012). Analysis of the specificity and selectivity of anti-EpCAM antibodies in breast cancer cell lines. Folia Histochem Cytobiol, 50, 534-41. crossref(new window)

34.
Stirpe F (2004). Ribosome-inactivating proteins. Toxicon, 44, 371-83. crossref(new window)

35.
Sudjadi, Witasari LD, Sadarum MT, et al (2007). Efek sitotoksik suatu protein seperti ribosome-inactivating proteins yang bersifat asam dari daun Mirabilis jalapa L. pada sel kanker. MFI, 18, 8-14.

36.
Sundar S, Kundu J, Kundu SC, et al (2010). Biopolymeric nanoparticles, Sci Technol Adv Mater, 11, 1-13.

37.
Torchilin VP, Lukyanov AN (2003). Peptide and protein drug delivery to and into tumors: challenges and solutions, Drug Discov Today, 8, 259-66. crossref(new window)

38.
Vauthier C, Bouchemal K (2009). Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res, 26, 1025-58. crossref(new window)

39.
Vivanco JM, Querci M, Salazar LF (1999). Antiviral and antiviroid activity of MAP-containing extracts from Mirabilis jalapa L. roots. Plant Dis, 83, 1116-21. crossref(new window)

40.
Zhang H, Wu S, Tao Y, et al (2010). Preparation and characterization of water-soluble chitosan nanoparticles as protein delivery system. J Nanomaterials, 2010, 1-5.